|
... certain stocks on your trading list. We have been all over the trends of late, calling them perfectly I am proud to say. For example, Plandai (OTCQB – PLPL)) might be the best performer of the year, ...
There is no other way of saying it. The market is ugly. We called it two weeks ago but through it might not happen until this week. Alas, we at least may get a strong sense of what lies ahead for the ...
With the announcement of its recent license agreement with Diego Pellicer, Inc. and Diego Pellicer Worldwide Inc., Plandaí Biotechnology, Inc. (OTCQB –PLPL - $0.49 – Spec Buy) has positioned itself at ...
As we have now entered 2014, the Company’s medical marijuana initiatives, announced in the fourth quarter of 2013, may take center stage now that the nation has overwhelmingly changed its stance toward ...
Obesity is now becoming a worldwide problem that is no longer confined solely to the United States. Finally classified as a disease by the AMA earlier this year, obesity prevalence has increased 40% in ...
In a move that we believe will add meaningful value to the overall company, Plandaí¬ Biotechnology, Inc. (OTCQB – PLPL - $0.51 – Spec Buy) recently announced that it has formed a new wholly-owned subsidiary, ...
In early 2014, the Company will launch a trial to test anti-aging properties of its topical cream delivered offering.
Investment and Company Research
Opportunity Research ...
Less than a month removed from acquiring rights to a cutting edge nano and micro particle entrapment technology, Plandaí Biotechnology, Inc. (OTCQB – PLPL) has already secured a lucrative out-licensing ...
With October (The Breast Cancer Awareness Month) around the corner, it is interesting to note that Plandaí¬ Biotechnology, Inc.’s (OTCQB – PLPL - $0.55 – Spec Buy) Phytofare™ Citrus Products may prove ...
Plandaí Biotechnology, Inc. (OTCQB – PLPL - $0.48 – Spec Buy) has made significant strides in recent months as it nears an inflection point which will migrate the Company from the development phase to ...
... fatty acids-based nano- and micro-particles, known as Pheroid. Under the terms of the world license, Plandai has the exclusive right to use the Pheroid technology with all Phytofare™ polyene-based extracts, ...
Plandaí Biotechnology’s key catalyst in product success is its bioavailability, or the level of absorption into the blood stream from the extracts. The Phytofare™ Limonoid Glycoside Complex product will ...
... Plandai's Phytofare™ extracts commence in 1Q14 as well.
Plandaí’s aggressive marketing campaign will reap major benefits as the message that beverages and other products that utilize the Phytofare™ ...
... market and distribute Plandai's Phytofare™ extracts in 1Q14 as well.
Plandaí’s aggressive marketing campaign will reap major benefits from the message that beverages and other products that utilize the ...
A research study published by a number of scientists in Italy demonstrates that green tea extracts do have a positive impact in treating malaria, in vitro, which confirms Plandai's study results.
Investment ...
As we near the end of the dog days of August, the relatively sleepy and under-followed Plandaí¬ Biotechnology, Inc. (OTCQB – PLPL - $0.61 - Spec Buy) has matched its 52-week high this week and appears ...
... non-exclusive rights to sell and market Plandai's Phytofare™ extracts into European markets.
This is a key alliance for Plandaí. Willow is a family-owned firm that specializes and targets ...
Plandaí Biotechnology, Inc. (OTCQB – PLPL - $0.53 - Spec Buy), which is slated engage in a weight loss study to test the efficacy of its flagship product, is well-positioned to assist in the fight against ...
With all of these positive attributes in its corner, Plandaí is on the verge of changing how we approach weight loss on its way to generating substantial revenue in the nutriceutical space.
Investment ...
Based on preliminary figures, the new IOGA contract could be worth over $200M in revenue and nearly $50M in EBITDA to INSCOR over the next 3 years.
Investment and Company ...
...
PLANDAI BIOTECHNOLOGY, INC.
Timeline of Upcoming Events Indicate Major Milestones Ahead
Rob Goldman
[email protected]
Aaron Schweitzer [email protected]
...
The poor side effect profile for an already approved malaria drug serves as a major boost to Plandai Biotechnology Inc.’s (OTCQB – PLPL - $0.47 - Spec Buy) new malaria treatment efforts.
Investment ...
...
July 25, 2013
Plandai: Green Tea Extracts Fight the Common Cold
According to the National Institute of Allergy and Infectious Diseases, Americans suffer from roughly 1 billion colds per year in the ...
LifeApps Digital Media, Inc. (OTCQB – LFAP) is a digital media company focusing on health, fitness, sports publications, and next-generation social networks. The Company leverages the hyper growth in digital ...
By engaging in the upcoming human clinical trials for its flagship product, trials, Plandai has the opportunity to be crowned the Green Tea Extract and bioavailability leader.
...
Clearly, whether EGCG is used alone or in conjunction with L-theanine, cognitive abilities can be aided via consumption of these nutrients. This opens up a whole new market for a company such as Plandaí ...
... Looking at the Company’s line of offerings, we believe that this will be the third product in the Plandai arsenal that will be marketed and sold in 2014. Among other approaches in marketing the ...
... 11, 2013
With Plandai’s Products, East Meets West
It is no secret that the origins of green tea and black tea are derived from nations in the Far East, such as China. The West was first introduced ...
... Research Opportunity Research MICROCAP HOT TOPICS
July 9, 2013
Plandai Primed To Fight Colon Cancer
Much has been written about colon cancer prevention and treatment. ...
... to illegal or banned performance enhancing drugs.
Investment and Company Research Opportunity Research MICROCAP HOT TOPICS
July 2, 2013
Plandai’s Natural Performance ...
Plandai’s Phytofare™ Catechin Complex is derived from Green Tea that could prove to be used to target the large anti-aging market. Catechins found in green tea, such as EGCG (Epigallocatechin Gallate), ...
...
June 26, 2013
Plandai’s Flagship Product Demonstrates Industry-Leading Efficacy In Killing Malaria Parasite
There are a number of companies that have conducted studies and tests ...
Plandai products may be used to treat high blood pressure
Investment and Company Research Opportunity Research MICROCAP HOT TOPICS
June 19, 2013
Plandai: A Calming ...
... by Plandai Biotechnology, Inc. (OTCQB – PLPL) which has made great strides toward treating and preventing malaria.
Investment and Company Research Opportunity Research MICROCAP HOT TOPICS ...
Recently published studies have indicated reduction in cholesterol levels. The common denominator in both trials is the correlation between green tea consumption and cholesterol reduction, along with overall ...
... – PLPL - $0.54 – Spec Buy)
Investment and Company Research
Opportunity Research
HOT TOPICS
June 11, 2013
PLANDAI’S ...
... for Alzheimer’s disease.
Investment and Company Research Opportunity Research MICROCAP HOT TOPICS
June 6, 2013
PLANDAI BENEFITS FROM INDUSTRY’S EGCG ALZHEIMER ...
...
Investment and Company Research
Opportunity Research
MICROCAP HOT TOPICS
June 4, 2013
Plandai ...
... MICROCAP HOT TOPICS
May 31, 2013
Plandai Could Revolutionize Malaria Treatment
Since the overwhelming majority of cases of malaria occur in ...
Plandai Biotechnology develops rich highly bioavailable extracts to treat diseases and medical conditions
Investment and Company Research
Opportunity ...
Until the arrival of Plandai Biotechnology, Inc. (OTCQB – PLPL), even many wellness pundits were unaware that substantial increases in bioavailability and effectiveness of some products, like green tea ...
|
||
|
|
||